How to Read a Clinical Trial Registration (NCT Entry)
ClinicalTrials.gov NCT entries contain structured data on study design, endpoints, eligibility, and status. This guide explains how to read an NCT entry and extract meaningful information about a peptide compound's clinical trial history.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
How to Read a Clinical Trial Registration: A Guide to ClinicalTrials.gov
ClinicalTrials.gov is the world's largest registry of clinical studies, maintained by the U.S. National Library of Medicine. As of 2025, the database contains over 500,000 registered studies from more than 220 countries. For researchers using the ClinicalPeptide reference database, understanding how to navigate and interpret trial registrations is an essential competency for contextualizing compound research within the clinical development pipeline.
This guide covers the anatomy of an NCT registration, phase terminology, how to interpret study status and endpoints, and how to connect registration records to published results.
What Is an NCT Number?
Every study registered on ClinicalTrials.gov is assigned a unique National Clinical Trial (NCT) identifier — a string in the format NCT followed by 8 digits (e.g., NCT02763345). This number:
- Serves as the permanent, canonical identifier for the study across all publications, press releases, and regulatory filings.
- Can be searched directly in PubMed (use the query
[si]field tag, e.g.,NCT02763345[si]) to find papers reporting results from that trial. - Is increasingly required by journals as a condition of publication for clinical trial results.
- Is used by the FDA and other regulatory agencies to link trial conduct to regulatory submissions.
When evaluating whether a published study was prospectively registered (a quality indicator that reduces selective outcome reporting), you can verify whether the NCT number in the published paper was registered before enrollment began by checking the "First Posted" date on ClinicalTrials.gov.
Study Phases: What They Mean
Clinical trials of investigational drugs are conducted in sequential phases, each designed to answer different questions about the compound's safety and efficacy profile. The phase designations used in ClinicalTrials.gov registrations follow FDA and ICH definitions.
Phase 1
Primary objective: Safety and pharmacokinetics in humans.
Phase 1 studies typically enroll small numbers of healthy volunteers (20–100 participants), though for oncology trials enrollment often consists of patients with the target disease. Key questions: What dose range is tolerable? What is the pharmacokinetic profile (absorption, distribution, metabolism, excretion) in humans? What adverse effects are observed and at what doses?
Phase 1 data establishes the Maximum Tolerated Dose (MTD) and informs the dose range to carry forward into Phase 2.
Phase 2
Primary objective: Preliminary efficacy signal and dose selection in the target population.
Phase 2 trials enroll patients with the disease or condition of interest (typically 50–300 participants). They assess whether the compound produces a measurable biological effect on the target endpoint, refine the dose selection, and gather additional safety data in the relevant patient population.
Phase 2 studies are often divided into Phase 2a (proof-of-concept, smaller) and Phase 2b (dose-ranging, larger). A positive Phase 2 result is the typical basis for advancing to Phase 3, though it does not confirm efficacy.
Phase 3
Primary objective: Definitive efficacy and safety in a large, controlled trial.
Phase 3 trials typically enroll hundreds to thousands of participants across multiple sites. They are typically randomized controlled trials (RCTs) — the gold standard for establishing treatment efficacy. Phase 3 results form the primary basis for regulatory approval submissions (NDA or BLA in the United States, MAA in the European Union).
Phase 4
Post-marketing surveillance in the approved indication.
Phase 4 studies occur after a drug has received regulatory approval. They may be required by the FDA (post-market commitment studies) or conducted voluntarily to explore new indications, compare with existing therapies, or gather long-term safety data in broader populations.
Primary vs. Secondary Endpoints
Every registered clinical trial must designate primary endpoints and, optionally, secondary endpoints. This distinction has major implications for how results should be interpreted.
Primary endpoints are the pre-specified outcomes the trial is designed and powered to detect. They are agreed upon before enrollment begins. A positive primary endpoint result (statistical significance on the pre-specified outcome) is the regulatory and scientific standard for a successful trial.
Secondary endpoints are additional outcomes measured in the same trial. They may include mechanistic, exploratory, or supportive measures. Because multiple secondary endpoints are tested in most trials, the probability of at least one false positive result is elevated (the multiple comparisons problem). Secondary endpoint results are considered hypothesis-generating, not confirmatory.
The distinction matters critically when reading abstracts: a trial that reports "improvement in secondary endpoints" but missed its primary endpoint should not be interpreted as evidence of efficacy. Conversely, large, well-powered trials that show effects across both primary and secondary endpoints strengthen causal inference.
Enrollment Status: Interpreting What You See
The "Status" field in a ClinicalTrials.gov registration is the first indicator of where a compound stands in its development pathway.
| Status | Meaning |
|---|---|
| Not yet recruiting | Trial approved and registered but enrollment has not begun |
| Recruiting | Actively enrolling participants |
| Active, not recruiting | Enrollment complete; study ongoing (participants being followed or treated) |
| Completed | Study finished; results may or may not be posted |
| Terminated | Study stopped before planned completion |
| Suspended | Temporarily halted, often for safety review |
| Withdrawn | Never started after registration |
Why Terminated Trials Are Still Informative
A terminated trial is not a waste of information. Studies are terminated for several reasons, and the reason matters:
- Safety concerns: Early termination for safety signals is the most important finding. A compound terminated for adverse effects provides critical safety information that shapes subsequent research.
- Futility: A pre-planned interim analysis found that the trial is unlikely to achieve its primary endpoint even if completed — suggesting lack of efficacy at the tested dose in the tested population.
- Business/funding reasons: The sponsor may have discontinued development for commercial rather than scientific reasons. The compound may still have biological activity.
- Protocol issues: Enrollment challenges, site problems, or protocol amendments can lead to termination unrelated to compound performance.
When reviewing terminated trials for a research compound, always check the Why Stopped field in the registration and, if available, the results posted on ClinicalTrials.gov or the linked publication. A terminated study that posted interim data may contain the only available human pharmacokinetic data for a compound.
Inclusion/Exclusion Criteria: Reading the Population Definition
The Eligibility section of a ClinicalTrials.gov registration defines the study population in precise terms. These criteria determine to whom results can be generalized.
Inclusion criteria define who can enroll (e.g., age range, diagnosis, biomarker status, baseline lab values).
Exclusion criteria define who cannot (e.g., comorbidities, concurrent medications, prior treatment history).
A common error in interpreting clinical trial results is applying findings to populations that were excluded from the study. For example, a peptide trial that excluded patients with renal impairment provides no direct pharmacokinetic or safety information for that population.
When reviewing trial registrations for peptide compounds in the peptide library, noting the enrolled population's characteristics helps interpret whether published results are relevant to a particular research question.
Sponsor vs. Collaborator: Who Is Running the Trial?
ClinicalTrials.gov distinguishes between:
Sponsor: The entity responsible for the trial — submits the IND (Investigational New Drug application), oversees regulatory compliance, and is legally responsible for the study. May be a pharmaceutical company, academic institution, government agency, or individual investigator.
Collaborator: Organizations providing funding, sites, or operational support but not holding primary regulatory responsibility.
The sponsor type has some relevance to research interpretation. Industry-sponsored trials have historically shown higher positive outcome rates than independently funded trials (Lundh et al., 2017; Cochrane Database of Systematic Reviews), a phenomenon attributed to a combination of publication bias, selective outcome reporting, and strategic trial design. This does not invalidate industry-sponsored data — it is context for critical appraisal.
Finding Results: The Results Tab and Linked Publications
Registered trials are required by law (under the FDA Amendments Act of 2007 and the Final Rule effective 2017) to post summary results to ClinicalTrials.gov within 12 months of study completion for applicable clinical trials. The Results tab of a registration, when populated, contains:
- Participant flow (enrollment, completions, withdrawals)
- Baseline demographic data
- Outcome measure results (primary and secondary endpoints with statistical analyses)
- Adverse events summary
To find published papers linked to a trial:
- Note the NCT number.
- Search PubMed:
NCT########[si](secondary identifier field). - Check the "References" section of the ClinicalTrials.gov record, which may include linked publications.
- Search for the compound name AND phase (e.g.,
"semaglutide" AND "Phase 3" AND "randomized") as a supplementary strategy.
Not all registered trials have published results, especially terminated studies. Unpublished trial data represents a well-documented source of publication bias (Dickersin & Min, 1993; JAMA).
Linking NCT Numbers to Peptide Research on ClinicalPeptide
For peptide compounds with active or completed clinical trial programs, relevant NCT numbers are referenced in the peptide library compound pages. This allows researchers to move directly from the ClinicalPeptide reference data to the trial registration for full design details and, where available, to posted results.
For an overview of the clinical development landscape across therapeutic areas, see the tools section.
References
- U.S. National Library of Medicine. ClinicalTrials.gov Protocol Registration and Results System. clinicaltrials.gov
- Lundh, A., et al. (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, Issue 2, MR000033.
- Dickersin, K., & Min, Y.I. (1993). Publication bias: the problem that won't go away. Annals of the New York Academy of Sciences, 703, 135–148.
- FDA. (2017). Clinical Trials Registration and Results Information Submission. 21 CFR Part 11.
- Zarin, D.A., et al. (2016). Trial reporting in ClinicalTrials.gov — the final rule. New England Journal of Medicine, 375(20), 1998–2004.